Large-scale preparation of key building blocks for the manufacture of fully synthetic macrolide antibiotics.

Key building blocks for the production of fully synthetic macrolides have been scaled-up in first time pilot plant and kilo-lab campaigns. These building blocks have supported the discovery of new macrolide antibiotics as well as ongoing preclinical studies.

Synthesis and biological evaluation of 8-aminomethyltetracycline derivatives as novel antibacterial agents.

The C-8 position of the tetracyclines has been largely underexplored because of limitations in traditional semisynthetic techniques. Employing a total synthetic approach allowed for modifications at the C-7 and C-8 positions, enabling the generation of structure-activity relationships for overcoming the two most common tetracycline bacterial-resistance mechanisms: ribosomal protection (tet(M)) and efflux (tet(A)). Ultimately, several compounds were identified with balanced activity against both Gram-positive and Gram-negative bacteria, including pathogens bearing both types of tetracycline-resistance mechanisms. Compounds were screened in a murine systemic infection model to rapidly identify compounds with oral bioavailability, leading to the discovery of several compounds that exhibited efficacy when administered orally in murine pyelonephritis and pneumonia models.

Fluorocyclines. 2. Optimization of the C-9 side-chain for antibacterial activity and oral efficacy.

Utilizing a fully synthetic route to tetracycline analogues, the C-9 side-chain of the fluorocyclines was optimized for both antibacterial activity and oral efficacy. Compounds were identified that overcome both efflux (tet(K), tet(A)) and ribosomal protection (tet(M)) tetracycline-resistance mechanisms and are active against Gram-positive and Gram-negative organisms. A murine systemic infection model was used as an oral efficacy screen to rapidly identify compounds with oral bioavailability. Two compounds were identified that exhibit both oral bioavailability in rat and clinically relevant bacterial susceptibility profiles against major respiratory pathogens. One compound demonstrated oral efficacy in rodent lung infection models that was comparable to marketed antibacterial agents.

Synthesis of L-kedarosamine in protected form and its efficient incorporation into an advanced intermediate to kedarcidin chromophore.

An efficient route to the complex L-kedarosamine alpha-glycosidic ether 2, a synthetic precursor to kedarcidin chromophore, is described. Central to the route, which is suitable for the preparation of multigram amounts of material, is a short synthetic sequence from D-threonine to protected L-kedarosamine derivatives and methodology for their alpha-selective coupling with appropriate hydroxyl acceptors.

Proteasome inhibition by a totally synthetic beta-lactam related to salinosporamide A and omuralide.

A new and effective proteasome inhibitor, beta-lactam 3, has been accessed enantioselectively by multistep synthesis from the readily prepared intermediates 7 and 8 which were joined by a [2 + 2]-cycloaddition reaction to form the spiro beta-lactam 9 stereoselectively. The intermediate 9 was converted to 3 in seven steps and 30% overall yield. The beta-lactam 3 is stable for many days in water at pH 7, in contrast to the natural beta-lactones salinosporamide A (1) and omuralide (2). In common with 1 and 2, the beta-lactam 3 effectively inhibits the mammalian proteasome.

Evidence for facile atropisomerism and simple (non-nucleophilic) biradical-forming cycloaromatization within kedarcidin chromophore aglycon.

The kinetics and thermodynamics of atropisomerism within the protected kedarcidin chromophore aglycon 8, as well as a series of ansa-bridged synthetic intermediates leading to 8, were determined by 1H NMR spectroscopy. The data show that the ratio of atropisomeric forms of chloropyridine-bridged ansa intermediates is subject to wide variation with seemingly subtle structural variation. The vinyl bromide 4, for example, in the first X-ray structure determination of a kedarcidin ansa-bridged system, was found to exist as a single atropisomer in the solid state, but a nearly equal mixture (K = 0.70) of isomers in solution (t1/2 for isomer interconversion approximately 0.2 s at 20 degrees C). The aglycon 8, a 2.2:1 mixture of atropisomers, was found to undergo direct unimolecular biradical-forming cycloaromatization at ambient temperature in a mixture of 1,4-cyclohexadiene-benzene, without nucleophilic activation. The product 9 was formed as a single atropisomer (k = 2 x 10-4 s-1, t1/2 = 58 min, 81% yield), suggesting that the rate of atropisomerism within 8 is rapid with respect to cycloaromatization. The rate of cycloaromatization of 8 was found to be highly solvent-dependent, being more rapid in the presence of a good hydrogen-atom donor, consistent with the earlier model studies of Hirama et al. that showed that certain nine-membered cyclic (Z)-enediynes may equilibrate with their biradical cycloaromatization products. Incubation of 8 with beta-mercaptoethanol, under conditions mimicking experiments leading to DNA cleavage with kedarcidin, showed no evidence for nucleophilic activation. The product of direct cycloaromatization (9) was isolated instead. The evidence suggests that kedarcidin, like the enediyne agent C-1027, is capable of spontaneous thermal biradical formation without prior chemical activation.